Cargando…

Human Soluble Recombinant Thrombomodulin, ART-123, Resolved Early Phase Coagulopathies, but Did Not Significantly Alter the 28 Day Outcome in the Treatment of DIC Associated with Infectious Systemic Inflammatory Response Syndromes

Disseminated intravascular coagulation (DIC) is a catastrophic systemic disorder of coagulation, resulting in uncontrollable bleeding, multiple organ failure, and death. Sepsis is one of the common causes of DIC. Despite many attempts to correct these coagulation pathologies, no adjunctive treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Shusuke, Ai, Tomohiko, Sera, Toshiki, Ochiai, Kanae, Otomo, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832475/
https://www.ncbi.nlm.nih.gov/pubmed/31569648
http://dx.doi.org/10.3390/jcm8101553
_version_ 1783466181365071872
author Mori, Shusuke
Ai, Tomohiko
Sera, Toshiki
Ochiai, Kanae
Otomo, Yasuhiro
author_facet Mori, Shusuke
Ai, Tomohiko
Sera, Toshiki
Ochiai, Kanae
Otomo, Yasuhiro
author_sort Mori, Shusuke
collection PubMed
description Disseminated intravascular coagulation (DIC) is a catastrophic systemic disorder of coagulation, resulting in uncontrollable bleeding, multiple organ failure, and death. Sepsis is one of the common causes of DIC. Despite many attempts to correct these coagulation pathologies, no adjunctive treatments have been shown to improve the mortality of DIC associated with sepsis. Although some clinical studies showed a recently developed human recombinant thrombomodulin, ART-123, might be effective in the treatment of DIC, few randomized, placebo-controlled studies have been conducted. In this study, we treated 60 DIC patients associated with systemic inflammatory response syndrome (SIRS) using ART-123 (n = 29) or saline as a placebo (n = 31). The basal clinical characteristics were similar in both groups. We compared clinical severity scores and DIC score in acute phase, and 28 day mortality between the two groups. Our study demonstrated the DIC score improved a few days earlier in the ART-123 group than the placebo group, and there were no major life-threatening adverse events in both groups. The overall survival rate at day 28 was not significantly altered. In conclusion, ART-123 can be used safely in DIC associated with infectious SIRS patients; however, its true efficacy in the treatment of DIC needs to be further investigated.
format Online
Article
Text
id pubmed-6832475
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68324752019-11-25 Human Soluble Recombinant Thrombomodulin, ART-123, Resolved Early Phase Coagulopathies, but Did Not Significantly Alter the 28 Day Outcome in the Treatment of DIC Associated with Infectious Systemic Inflammatory Response Syndromes Mori, Shusuke Ai, Tomohiko Sera, Toshiki Ochiai, Kanae Otomo, Yasuhiro J Clin Med Article Disseminated intravascular coagulation (DIC) is a catastrophic systemic disorder of coagulation, resulting in uncontrollable bleeding, multiple organ failure, and death. Sepsis is one of the common causes of DIC. Despite many attempts to correct these coagulation pathologies, no adjunctive treatments have been shown to improve the mortality of DIC associated with sepsis. Although some clinical studies showed a recently developed human recombinant thrombomodulin, ART-123, might be effective in the treatment of DIC, few randomized, placebo-controlled studies have been conducted. In this study, we treated 60 DIC patients associated with systemic inflammatory response syndrome (SIRS) using ART-123 (n = 29) or saline as a placebo (n = 31). The basal clinical characteristics were similar in both groups. We compared clinical severity scores and DIC score in acute phase, and 28 day mortality between the two groups. Our study demonstrated the DIC score improved a few days earlier in the ART-123 group than the placebo group, and there were no major life-threatening adverse events in both groups. The overall survival rate at day 28 was not significantly altered. In conclusion, ART-123 can be used safely in DIC associated with infectious SIRS patients; however, its true efficacy in the treatment of DIC needs to be further investigated. MDPI 2019-09-27 /pmc/articles/PMC6832475/ /pubmed/31569648 http://dx.doi.org/10.3390/jcm8101553 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mori, Shusuke
Ai, Tomohiko
Sera, Toshiki
Ochiai, Kanae
Otomo, Yasuhiro
Human Soluble Recombinant Thrombomodulin, ART-123, Resolved Early Phase Coagulopathies, but Did Not Significantly Alter the 28 Day Outcome in the Treatment of DIC Associated with Infectious Systemic Inflammatory Response Syndromes
title Human Soluble Recombinant Thrombomodulin, ART-123, Resolved Early Phase Coagulopathies, but Did Not Significantly Alter the 28 Day Outcome in the Treatment of DIC Associated with Infectious Systemic Inflammatory Response Syndromes
title_full Human Soluble Recombinant Thrombomodulin, ART-123, Resolved Early Phase Coagulopathies, but Did Not Significantly Alter the 28 Day Outcome in the Treatment of DIC Associated with Infectious Systemic Inflammatory Response Syndromes
title_fullStr Human Soluble Recombinant Thrombomodulin, ART-123, Resolved Early Phase Coagulopathies, but Did Not Significantly Alter the 28 Day Outcome in the Treatment of DIC Associated with Infectious Systemic Inflammatory Response Syndromes
title_full_unstemmed Human Soluble Recombinant Thrombomodulin, ART-123, Resolved Early Phase Coagulopathies, but Did Not Significantly Alter the 28 Day Outcome in the Treatment of DIC Associated with Infectious Systemic Inflammatory Response Syndromes
title_short Human Soluble Recombinant Thrombomodulin, ART-123, Resolved Early Phase Coagulopathies, but Did Not Significantly Alter the 28 Day Outcome in the Treatment of DIC Associated with Infectious Systemic Inflammatory Response Syndromes
title_sort human soluble recombinant thrombomodulin, art-123, resolved early phase coagulopathies, but did not significantly alter the 28 day outcome in the treatment of dic associated with infectious systemic inflammatory response syndromes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832475/
https://www.ncbi.nlm.nih.gov/pubmed/31569648
http://dx.doi.org/10.3390/jcm8101553
work_keys_str_mv AT morishusuke humansolublerecombinantthrombomodulinart123resolvedearlyphasecoagulopathiesbutdidnotsignificantlyalterthe28dayoutcomeinthetreatmentofdicassociatedwithinfectioussystemicinflammatoryresponsesyndromes
AT aitomohiko humansolublerecombinantthrombomodulinart123resolvedearlyphasecoagulopathiesbutdidnotsignificantlyalterthe28dayoutcomeinthetreatmentofdicassociatedwithinfectioussystemicinflammatoryresponsesyndromes
AT seratoshiki humansolublerecombinantthrombomodulinart123resolvedearlyphasecoagulopathiesbutdidnotsignificantlyalterthe28dayoutcomeinthetreatmentofdicassociatedwithinfectioussystemicinflammatoryresponsesyndromes
AT ochiaikanae humansolublerecombinantthrombomodulinart123resolvedearlyphasecoagulopathiesbutdidnotsignificantlyalterthe28dayoutcomeinthetreatmentofdicassociatedwithinfectioussystemicinflammatoryresponsesyndromes
AT otomoyasuhiro humansolublerecombinantthrombomodulinart123resolvedearlyphasecoagulopathiesbutdidnotsignificantlyalterthe28dayoutcomeinthetreatmentofdicassociatedwithinfectioussystemicinflammatoryresponsesyndromes